2nd June 10:30
Exsulin research (diabetes blindness kidney heart rheumatoid arthritis)
- - -
New words, Insulinitis and Cellosis, used to supplement the
old words which are used to describe those conditions in
the following web article:
- - -
March 25, 2010
More than $1 million in federal funds to develop new ways
to reverse Insulinitis (type 1 diabetes)
- - -
Researchers at the Eastern Virginia Medical School Strelitz
Diabetes Center have been awarded a $1,076,250 grant by
the Department of Defense (DoD) Peer Reviewed Medical
Research Program to develop new ways of reversing the
underlying causes of Insulinitis (Type 1 diabetes).
David Taylor-Fishwick, PhD, associate professor of internal
medicine and director of the Cell, Molecular and Islet Biology
Laboratory, leads the team whose research applies to both
regenerative and autoimmune medicine.
"Insulinitis (Type 1 diabetes) is caused by an autoimmune
attack that destroys the insulin-producing beta cells, and the
body does not automatically regenerate or replace these cells,"
explains Dr. Taylor-Fishwick. "The unique challenge in reversing
Insulinitis (Type 1 diabetes) is to regenerate the insulin-producing
beta cells and to stop the body's autoimmune attack."
Insulin is the hormone that helps the body convert glucose from
food into energy. When the beta cells are destroyed, no insulin
can be produced. Insulin replacement therapy helps the body
maintain normal glucose levels, but doesn't prevent the serious
diabetes health problems such as blindness, nerve damage, heart
disease and kidney failure.
Dr. Taylor-Fishwick's research on beta cell regeneration has
focused on INGAP (Islet Neogenesis Associated Protein),
branded as Exsulin, the breakthrough discovery made by Aaron
I. Vinik, PhD, MD, director of research at the Strelitz Diabetes
Center, and Dr. Lawrence Rosenberg of McGill University. Pub-
lished trials of Exsulin demonstrated promising results in both
Insulinitis (Type 1 diabetes) and Cellosis (Type 2 diabetes)
The DoD grant will fund the next phase in the team's research
finding a way to neutralize the immune system's attack of the beta
cells. This immune attack occurs at the onset of Insulinitis (Type 1
diabetes) and may continue after Insulinitis (Type 1 diabetes) has
appeared. The benefits of this research may also apply to other
autoimmune diseases such as lupus and rheumatoid arthritis.
Dr. Taylor-Fishwick and his team will test several experimental
drugs developed by Jerry Nadler, MD, chair of internal medicine
and director of the EVMS Strelitz Diabetes Center. The compounds
are designed to modify the autoimmune response and stabilize beta
cells. The goal is to develop these compounds into an oral pill.
"The Department of Defense, through its Congressionally Directed
Medical Research Program, is especially interested in research to
combat autoimmunity," Dr. Taylor-Fishwick says. "So part of our
work is to block the process of autoimmunity that occurs in Insulinitis
(Type 1 diabetes). We are using a drug called Lisofylline (LSF) and
related molecules to block interleukin-12, a protein that triggers the
autoimmune response," he explains. "By targeting interleukin-12 sig-
naling, we hope to redirect the immune system, but not wipe it
The researchers hope that one of these compounds, when used in
conjunction with Exsulin, may help to create a combination therapy
regimen that could achieve a functional cure for Insulinitis (Type 1
About Exsulin: Exsulin Corporation is a the****utic development
company targeting regeneration of insulin-producing cells. Exsulin
Corporation holds the global, exclusive license for INGAP and is
the sponsor of a Phase II clinical trial with its lead compound,
Exsulin, that is currently enrolling patients at Mayo Clinic and
McGill University. The trial is targeted at regeneration of insulin-
producing cells from a patient's own pancreas in people with
established Insulinitis (Type 1 diabetes).
- - - end excerpts - - -
What is Insulinitis?
What is Cellosis?
- - -